ONCYOncolytics BiotechRunning, no new patients
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
Breast Cancer Metastatic
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 48 (final count)
- Started
- Jun 10, 2020
- Main results expected
- Aug 1, 2022
- Fully finished
- Jun 2025
- Results posted
- Jan 16, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Response Rate
Measured over: at week 16
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04215146 · record last updated 2025-01-16 · checked 2026-11-09 15:47 UTC